21.34
price up icon0.09%   0.02
pre-market  Pre-mercato:  21.34  
loading

Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie

pulisher
Sep 30, 2025

Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury

Sep 30, 2025
pulisher
Sep 30, 2025

Why ACADIA Pharmaceuticals Inc. stock could be next big winner2025 Dividend Review & Entry Point Confirmation Signals - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

News impact scoring models applied to ACADIA Pharmaceuticals Inc.Price Action & Reliable Volume Spike Trade Alerts - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

JP Morgan Updates ACADIA Pharmaceuticals (ACAD) Analyst Rating | - GuruFocus

Sep 29, 2025
pulisher
Sep 29, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $33.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Will ACADIA Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWeekly Investment Report & Verified Swing Trading Watchlist - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Insider Selling & Real-Time Stock Movement Alerts - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps - MSN

Sep 28, 2025
pulisher
Sep 28, 2025

What analysts say about ACADIA Pharmaceuticals Inc stockMomentum Stock Picks & Budget Friendly Growth - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

What drives ACADIA Pharmaceuticals Inc stock priceAnalyst Downgrades & Market Crushing Stock Picks - Early Times

Sep 27, 2025
pulisher
Sep 27, 2025

What machine learning models say about ACADIA Pharmaceuticals Inc.Index Update & Long-Term Growth Plans - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AIInsider Selling & Stepwise Trade Execution Plans - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

Using flow based indicators on ACADIA Pharmaceuticals Inc.2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

Acadia drops development of carbetocin in PWS - The Pharma Letter

Sep 26, 2025
pulisher
Sep 25, 2025

Acadia to stop development of rare disease therapy after trial failure - ET Pharma

Sep 25, 2025
pulisher
Sep 25, 2025

ACADIA Pharmaceuticals Hits Day Low of $20.03 Amid Price Pressure - Markets Mojo

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals stock price target maintained by BMO after trial miss - Investing.com Canada

Sep 25, 2025
pulisher
Sep 25, 2025

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - sharewise.com

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says - MarketScreener

Sep 25, 2025
pulisher
Sep 25, 2025

A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $35 - 富途牛牛

Sep 25, 2025
pulisher
Sep 25, 2025

Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating - MarketScreener

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia, Harmony record late-stage rare disease failures - pharmaphorum

Sep 25, 2025
pulisher
Sep 25, 2025

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - BioSpace

Sep 25, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock price target lowered to $35 at TD Cowen - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Gives Up In PWS After Another ACP-101 Phase III Miss - insights.citeline.com

Sep 24, 2025
pulisher
Sep 24, 2025

Oppenheimer cuts Acadia Pharmaceuticals stock price target after failed study By Investing.com - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno - Fierce Pharma

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals: Reeling After PWS FailureDowngrading To Hold (NASDAQ:ACAD) - Seeking Alpha

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint By Investing.com - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges - MSN

Sep 24, 2025
pulisher
Sep 24, 2025

BMO Capital reiterates Acadia Pharmaceuticals stock rating despite trial failure - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq

Sep 24, 2025
pulisher
Sep 24, 2025

ACAD: Latest Developments and Market Insights - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Faces Setback After Phase 3 Trial Results - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

ACADIA Pharmaceuticals (ACAD): Needham Lowers Price Target, Maintains Buy Rating | ACAD Stock News - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down Following Analyst Downgrade - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia to scrap Prader-Willi drug after study setback - BioPharma Dive

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Needham & Company LLC Has Lowered Expectations for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals stock unchanged as BofA maintains Neutral rating By Investing.com - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia, with a failed phase III, drops Prader-Willi candidate - BioWorld MedTech

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia’s phase 3 trial for Prader-Willi syndrome drug fails to meet goals - Investing.com Australia

Sep 24, 2025
pulisher
Sep 24, 2025

Traders Buy Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD) - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Experiences Significant Drop in St - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target - TipRanks

Sep 24, 2025
pulisher
Sep 24, 2025

Leerink on Acadia (ACAD): 'Despite the news, we still like the stock' - StreetInsider

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Scraps Prader-Willi Drug After Late-Stage Failure - BioSpace

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals (ACAD) Shares Dip After Trial Disappointm - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Lithium Americas, Oracle, Acadia Pharma: Trending Tickers - Yahoo Finance

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharma (ACAD) Shares Plunge After Prader-Willi Drug Setba - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Stifel maintains Hold rating on Acadia Pharmaceuticals stock after drug failure By Investing.com - Investing.com South Africa

Sep 24, 2025
pulisher
Sep 24, 2025

ACAD Stock Falls as Phase 3 Trial Results Disappoint - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Stifel maintains Hold rating on Acadia Pharmaceuticals stock after drug failure - Investing.com

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study - statnews.com

Sep 24, 2025
pulisher
Sep 24, 2025

ACAD Faces Setback as Phase 3 Trial Fails - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia (ACAD) Trial Results Impact Soleno Stock - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

BMO Capital: 'expect ACAD shares to decline' - StreetInsider

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals down 13% after COMPASS PWS trial misses endpoints - TipRanks

Sep 24, 2025
pulisher
Sep 24, 2025

Acadia Pharmaceuticals' ACP-101 for Hyperphagia in Prader-Willi Syndrome Fails to Meet Primary Endpoint in Phase 3 Trial - MarketScreener

Sep 24, 2025
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Capitalizzazione:     |  Volume (24 ore):